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Background: Previous data indicate that purified components of ginseng can inhibit HIV reverse transcriptase
in vitro, suggesting that ginseng components in plasma may interfere with HIV-1 RNA detection assays.
Methods: Pre- and post-dose plasma from three volunteers dosed with 3000 mg American ginseng was spiked
with HIV and analyzed by the Roche COBAS Ampliprep/Taqman v2.0 HIV-1 RNA assay.
Results: Presence of American ginseng had no significant effect on measured HIV-1 RNA concentration. Variation
within pre- and post-dose plasma pair was insignificant and within assay performance limits.
Conclusion: Plasma from subjects dosed with 3000 mg American ginseng does not interfere with the Roche
COBAS Ampliprep/Taqman v2.0 HIV-1 RNA assay. This implies that in vitro inhibition of HIV reverse transcriptase
by American ginseng components is unlikely to be clinically relevant.Background
American ginseng is used to ameliorate HIV-associated
fatigue [1]. Recent reports have indicated that protein
components of Asian ginseng (Panax ginseng and Panax
notoginseng) can inhibit HIV-1 reverse transcriptase and
other polymerases in vitro [2,3]. Data from the literature
suggests that it is unlikely that protein components of
orally-dosed ginseng are bioavailable at relevant concen-
trations, or survive the processing required to quantify
plasma HIV-1 RNA concentrations [4,5]. However, these
findings raised concerns that ginseng components may
interfere with reverse transcriptase-dependent assays used
to determine plasma HIV-1 RNA concentration, and po-
tentially confound clinical management of this disease.
We hypothesized that standardized American ginseng
would not affect the performance of the Roche COBAS
Ampliprep/Taqman v2.0 HIV-1 RNA assay (Limit of* Correspondence: aandrade@jhmi.edu
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unless otherwise stated.Detection 20 copies/ml) used in clinical practice to quan-
tify plasma HIV-1 RNA. American ginseng was selected
for this experiment because we used this dietary supple-
ment in our previous studies [6,7]. We tested our hypoth-
esis by measuring the performance of the Roche COBAS
Ampliprep/Taqman v2.0 HIV-1 RNA assay [4] in plasma
of volunteers receiving high-dose American ginseng.Methods
De-identified archived plasma samples from healthy vol-
unteers and HIV-infected patients were utilized with
Johns Hopkins Medicine Institutional Review Board ap-
proval. Test samples had been archived from a previous
study (NCT01136928, www.clinicaltrials.gov) in healthy
volunteers dosed orally with 3000 mg daily of American
ginseng for 14 days. Selection of a 14-day dosing period
was based on the principle that it can take up to two
weeks for maximal induction of drug metabolizing en-
zymes involved in the biotransformation of pharmaco-
logical compounds. The American ginseng capsules used
in our previous studies were made from ground root fromtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(Wasau, WI). The sample of American ginseng was stan-
dardized to ≥5% total ginsenosides, plant steroids of the
saponin class that are thought to be the active ingredients
of this dietary supplement [8]. The following ginsenoside
concentrations were detected by HPLC analysis: Rg1 1.02
mg/g, Re 14.81 mg/g, Rb1 34.28 mg/g, Rc 4.69 mg/g, Rb2
0.65 mg/g, Rb3 0.98 mg/g, and Rd 6.65 mg/g. The sample
was also tested for common contaminants including bac-
teria, fungi, and heavy metals. Ginsenoside plasma con-
centrations were not measured.
Plasma samples obtained at 4 hours post-dose were
utilized for the study since it has been demonstrated that
ginsenoside Rb1 concentration peaks approximately 4 h
post-dose [9]. HIV RNA-containing plasma was obtained
from the Johns Hopkins Pathology plasma bank. One
hundred twenty μl of plasma with HIV RNA concentra-
tion of 2,177,772 copies/ml was added to 1080 μl test
plasma without and with American ginseng. The high
HIV RNA concentration was selected to discern between
a potential effect of American ginseng on the Cobas
assay versus a dilution effect. Matched sample pairs
from three volunteers were utilized for the test. We se-
lected three plasma samples of American ginseng based
on the assumption that if the assay inhibition was rele-
vant and robust, the effect of American ginseng would
have been seen in a few samples with this high dose of
American ginseng.
Plasma HIV-1 RNA concentration in these spiked sam-
ples was determined using the Roche COBAS Ampliprep/
Taqman v2.0 HIV-1 RNA assay with an internal control
(Limit of Detection 20 copies/ml).
Results and discussion
In all three plasma pairs (Table 1), the presence of
American ginseng had no significant effect on measured
plasma HIV-1 RNA concentrations. Log10 plasma HIV-1
RNA ranged from 6.02 to 6.09. This variation is negligible
and within assay performance limits [4].
These results establish that the Roche COBAS Ampli-
prep/Taqman v2.0 HIV-1 RNA assay does not suffer
from interference when used with plasma from subjects
receiving American ginseng.
Our study had some limitations: 1) The American
ginseng sample tested in our experiments was standardized
to ≥5% total ginsenosides and also tested for potentialTable 1 Effect of American ginseng on plasma HIV RNA meas
Sample set 1 2
- ginseng + ginseng -
HIV-RNA (copies/ml) 1109720 1122310 1
HIV RNA (Log10) 6.05 6.05
Roche COBAS Ampliprep/Taqman v2.0 HIV-1 RNA assay (Limit of detection 20 copiecontaminants, as recommended in the literature. There-
fore, our results cannot be generalized to other studies that
do not follow these recommended standardization proce-
dures; 2) Because ginsenosides or other American ginseng
components were not measured in the test samples, we are
uncertain about the concentration of American ginseng
components in systemic circulation at the time the plasma
was sampled. However, previous pharmacokinetic studies
[9] have suggested that peak ginsenoside plasma concen-
trations should occur around the time point we examined;
3) The lack of effect on the COBAS plasma HIV RNA
assay described here might not be generalizable to other
species, formulations and plant parts of ginseng. Ginseng
consists of at least 10 species within the genus Panax that
are indigenous to Asia (Chinese, Japanese, and Sanchi gin-
seng) and North America (Panax quinquefolius) [8]. There
are more than 30 identified ginsenosides, which vary in
number and concentration from one species of ginseng to
another [8]. These variances in ginsenoside concentrations
could potentially lead to a different effect on the perform-
ance of HIV RNA assays depending on the species of gin-
seng being tested. Also, the roots, berries, and leaves of the
ginseng plant are known to contain different concentra-
tions of ginsenosides. Since our study used powdered gin-
seng root, the lack of effect of other parts of the ginseng
plant on this viral assay would need to be verified. In
addition, difference in ginseng formulations, including dis-
similarity in excipient content, is another potential factor
that could potentially lead to different effects on the per-
formance of HIV RNA assays. 4) Finally, our experiment
tested samples from subjects taking 3000 mg daily of
American ginseng for 14 days, which was the highest dose
used in one of our previous studies (NCT01136928, www.
clinicaltrials.gov). The effects of higher doses or treatment
duration with American ginseng on viral assays would re-
quire further investigation.
Conclusions
In conclusion, plasma from subjects taking high-dose
standardized American ginseng did not interfere with the
Roche COBAS Ampliprep/Taqman v2.0 HIV-1 RNA assay
performance. These results also suggest that ginseng in-
duced HIV-1 reverse transcriptase inhibition demon-
strated in vitro [2,3] is unlikely to be clinically relevant.
This finding provides much needed data on the effects of
dietary supplements on laboratory tests commonly usedurement
3
ginseng + ginseng - ginseng + ginseng
218900 1165710 1032900 1191440
6.09 6.07 6.02 6.08
s/ml).
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significant concern since the use of herbals and botanicals
is common in the HIV-infected community in the United
States and in other countries.
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